N Engl J Med 392(6):612615 [DOI] [PubMed] [Google Scholar] 28.Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Although the results of numerous studies can be accessed, the majority only included small populations and so the outcomes of therapy could not be accurately evaluated
What Needs to Be in Place Before a First-in-Human Trial Begins Before entering a First-in-Human trial, a drug candidate must be supported by a comprehensive package of scientific, non-clinical and quality evidence
Once you finish the survey and enter your email, Noom will send your personalized results straight to your inbox
10.1161/01.CIR.0000147829.78357.C5 [DOI] [PubMed] [Google Scholar] 204.Kuhn M
Cardiovascular Benefits The cardiovascular benefit profile of retatrutide extends beyond what weight loss alone would predict
